Atrial arrhythmias, a major contributor to cardiovascular morbidity, are believed to be influenced by 
autonomic nervous system tone. The main purpose of this invention was to highlight new findings that have emerged in the study of effects of 
autonomic nervous system tone on 
atrial arrhythmias, and its interaction with 
class III antiarrhythmic 
drug effects. This invention evaluates the significance of sympathetic and parasympathetic activation by determining the effects of 
autonomic nervous system using a vagal and stellar ganglions stimulation, and by using autonomic 
nervous system neurotransmitters infusion (norepinephrine, 
acetylcholine). This invention evaluates the autonomic 
nervous system effects on the atrial effective 
refractory period duration and dispersion, atrial conduction velocity, atrial 
wavelength duration, excitable gap duration during a stable circuit (such 
atrial flutter circuit around an anatomical obstacle), and on the susceptibility of occurrence (
initiation, maintenance and termination) of atrial re-entrant arrhythmias in canine. This invention also evaluates whether autonomic 
nervous system activation effects via a local neurotransimitters infusion into the right atria can alter those of 
class III antiarrhythmic 
drug, sotalol, during a sustained 
right atrial flutter. This invention represents an emergent need to set-up and develop a new class of anti-
cholinergic drug therapy for the treatment of 
atrial arrhythmias and to combine this new anti-
cholinergic class to antiarrhythmic drugs. Furthermore, this invention also highlights the importance of a local application of parasympathetic neurotransmitters / blockers and a 
catheter ablation of the area of 
right atrium with the highest density of parasympathetic fibers innervation. This may significantly reduce the occurrence of 
atrial arrhythmias and may preserve the antiarrhythmic effects of any drugs used for the treatment of atrial re-entrant arrhythmias.